Kenvue Inc. (NYSE:KVUE) Given Average Recommendation of “Hold” by Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have earned an average rating of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Twelve investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $19.2727.

KVUE has been the topic of several recent analyst reports. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th.

Kenvue Stock Down 0.0%

Kenvue stock opened at $19.20 on Monday. The stock has a market cap of $36.87 billion, a price-to-earnings ratio of 22.06, a PEG ratio of 1.37 and a beta of 0.47. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company’s 50-day moving average price is $18.95 and its two-hundred day moving average price is $18.14. Kenvue has a 52 week low of $14.02 and a 52 week high of $21.84.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share. On average, analysts expect that Kenvue will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Institutional Investors Weigh In On Kenvue

A number of institutional investors and hedge funds have recently bought and sold shares of KVUE. Port Capital LLC bought a new position in shares of Kenvue during the 2nd quarter valued at about $282,000. Caisse de depot et placement du Quebec bought a new stake in shares of Kenvue in the 2nd quarter worth approximately $16,141,000. Sculptor Capital LP bought a new stake in shares of Kenvue in the 2nd quarter worth approximately $77,443,000. Odyssean LLC acquired a new stake in Kenvue during the second quarter valued at approximately $530,000. Finally, Man Group plc acquired a new stake in Kenvue during the second quarter valued at approximately $80,461,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.